Melenikiotou Georgia
Known title: DirectorCIK: 0001817552
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Pulmonx Sets Q3 2026 Earnings Date for October 27. Pulmonx Corporation has announced that it will report its third-quarter 2026 financial results on October 27, 2026. This scheduled update provides a specific timeline for investors to review the company's latest performance metrics. The announcement serves as a standard corporate disclosure rather than a change in business operations.
Transaction History
| INSP | ▲ Buy | Grant | 344 | $0 | 7/15/2026 | View on chart |
| LUNG | ▲ Buy | Grant | 40,000 | $0 | 6/5/2026 | View on chart |
| INSP | ▼ Sell | Tax Withholding | 50 | $3K | 5/1/2026 | View on chart |
| INSP | ▲ Buy | Grant | 3,562 | $0 | 4/30/2026 | View on chart |
| INSP | ▲ Buy | Grant | 307 | $16K | 4/15/2026 | View on chart |
| INSP | ▲ Buy | Grant | 180 | $17K | 1/15/2026 | View on chart |
| INSP | ▲ Buy | Grant | 229 | $18K | 10/14/2025 | View on chart |
| INSP | ▲ Buy | Grant | 131 | $17K | 7/15/2025 | View on chart |
| LUNG | ▲ Buy | Grant | 37,153 | $0 | 6/2/2025 | View on chart |
| INSP | ▼ Sell | Tax Withholding | 35 | $0 | 5/2/2025 | View on chart |
| INSP | ▲ Buy | Grant | 1,266 | $0 | 5/1/2025 | View on chart |
| INSP | ▲ Buy | Grant | 102 | $15K | 4/14/2025 | View on chart |
| INSP | ▲ Buy | Grant | 80 | $14K | 1/15/2025 | View on chart |
| INSP | ▲ Buy | Grant | 79 | $17K | 10/14/2024 | View on chart |
| INSP | ▲ Buy | Grant | 32 | $4K | 7/15/2024 | View on chart |
| LUNG | ▲ Buy | Grant | 15,216 | $0 | 6/3/2024 | View on chart |
| INSP | ▲ Buy | Grant | 716 | $0 | 5/2/2024 | View on chart |
| INSP | ▲ Buy | Grant | 56 | $13K | 4/12/2024 | View on chart |
| INSP | ▲ Buy | Grant | 8 | $1K | 1/16/2024 | View on chart |
| INSP | ▲ Buy | Grant | 80 | $15K | 1/16/2024 | View on chart |
| INSP | ▲ Buy | Grant | 2 | $652 | 1/16/2024 | View on chart |
| INSP | ▲ Buy | Grant | 91 | $14K | 10/13/2023 | View on chart |
| INSP | ▲ Buy | Grant | 42 | $14K | 7/17/2023 | View on chart |
| LUNG | ▲ Buy | Grant | 12,620 | $0 | 6/1/2023 | View on chart |
| INSP | ▲ Buy | Grant | 669 | $0 | 4/27/2023 | View on chart |
| INSP | ▲ Buy | Grant | 59 | $14K | 4/10/2023 | View on chart |
| INSP | ▲ Buy | Grant | 55 | $14K | 1/10/2023 | View on chart |
| INSP | ▲ Buy | Grant | 81 | $14K | 10/11/2022 | View on chart |
| INSP | ▲ Buy | Grant | 70 | $14K | 7/11/2022 | View on chart |
| LUNG | ▲ Buy | Grant | 5,600 | $0 | 6/1/2022 | View on chart |
| INSP | ▲ Buy | Grant | 54 | $14K | 4/8/2022 | View on chart |
| INSP | ▲ Buy | Grant | 60 | $14K | 1/10/2022 | View on chart |
| INSP | ▲ Buy | Grant | 59 | $14K | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays Starts Coverage of Inspire Medical with Underweight
Barclays has begun coverage of Inspire Medical Systems and assigned an Underweight rating. The firm set a price target of $65 for the stock. This rating follows the recent analyst activity on the company. The stock is currently near its long‑term support level.
Barclays Starts Coverage of Inspire Medical with Underweight. Barclays has begun coverage of Inspire Medical Systems and assigned an Underweight rating. The firm set a price target of $65 for the stock. This rating follows the recent analyst activity on the company. The stock is currently near its long‑term support level.